Pulmonary Circulation (Jan 2025)
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)
- Lindsay M. Forbes,
- Natalie Bauer,
- Aritra Bhadra,
- Harm J. Bogaard,
- Gaurav Choudhary,
- Kara N. Goss,
- Stefan Gräf,
- Gustavo A. Heresi,
- Rachel K. Hopper,
- Arun Jose,
- Yunhye Kim,
- Timothy Klouda,
- Tim Lahm,
- Allan Lawrie,
- Peter J. Leary,
- Jane A. Leopold,
- Suellen D. Oliveira,
- Sasha Z. Prisco,
- Ruslan Rafikov,
- Christopher J. Rhodes,
- Duncan J. Stewart,
- Rebecca R. Vanderpool,
- Ke Yuan,
- Alexsandra Zimmer,
- Anna R. Hemnes,
- Vinicio A. deJesus Perez,
- Martin R. Wilkins
Affiliations
- Lindsay M. Forbes
- Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Aurora Colorado USA
- Natalie Bauer
- Department of Pharmacology College of Medicine, University of South Alabama Mobile Alabama USA
- Aritra Bhadra
- Department of Pharmacology College of Medicine, University of South Alabama Mobile Alabama USA
- Harm J. Bogaard
- Department of Pulmonary Medicine Amsterdam UMC Amsterdam Netherlands
- Gaurav Choudhary
- Division of Cardiology Warren Alpert Medical School of Brown University Providence Rhode Island USA
- Kara N. Goss
- Department of Medicine and Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA
- Stefan Gräf
- Division of Computational Genomics and Genomic Medicine, Department of Medicine University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute Cambridge UK
- Gustavo A. Heresi
- Division of Pulmonary Medicine Cleveland Clinic Cleveland Ohio USA
- Rachel K. Hopper
- Department of Pediatrics Stanford University School of Medicine Palo Alto California USA
- Arun Jose
- Division of Pulmonary, Critical Care, and Sleep Medicine University of Cincinnati Cincinnati Ohio USA
- Yunhye Kim
- Division of Pulmonary Medicine Boston Children's Hospital Boston MA USA
- Timothy Klouda
- Division of Pulmonary Medicine Boston Children's Hospital Boston MA USA
- Tim Lahm
- Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Aurora Colorado USA
- Allan Lawrie
- National Heart and Lung Institute Imperial College London London UK
- Peter J. Leary
- Departments of Medicine and Epidemiology University of Washington Seattle Washington USA
- Jane A. Leopold
- Division of Cardiovascular Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
- Suellen D. Oliveira
- Department of Anesthesiology, Department of Physiology and Biophysics University of Illinois at Chicago Chicago Illinois USA
- Sasha Z. Prisco
- Division of Cardiovascular Lillehei Heart Institute, University of Minnesota Minneapolis Minnesota USA
- Ruslan Rafikov
- Department of Medicine Indiana University Indianapolis Indiana USA
- Christopher J. Rhodes
- National Heart and Lung Institute Imperial College London London UK
- Duncan J. Stewart
- Ottawa Hospital Research Institute Faculty of Medicine University of Ottawa Ottawa Ontario Canada
- Rebecca R. Vanderpool
- Division of Cardiovascular Medicine The Ohio State University Columbus Ohio USA
- Ke Yuan
- Division of Pulmonary Medicine Boston Children's Hospital Boston MA USA
- Alexsandra Zimmer
- Department of Medicine Brown University Providence Rhode Island USA
- Anna R. Hemnes
- Division of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA
- Vinicio A. deJesus Perez
- Division of Pulmonary and Critical Care Medicine Stanford University Medical Center Stanford California USA
- Martin R. Wilkins
- National Heart and Lung Institute Imperial College London London UK
- DOI
- https://doi.org/10.1002/pul2.70027
- Journal volume & issue
-
Vol. 15,
no. 1
pp. n/a – n/a
Abstract
ABSTRACT Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor, and treat pulmonary vascular disease is increasingly possible with the growing accessibility of powerful clinical and research tools. Nevertheless, challenges exist in implementing these tools to optimal effect. The 2023 Grover Conference Series reviewed the research landscape to summarize the current state of the art and provide a better understanding of the application of precision medicine to managing pulmonary vascular disease. In particular, the following aspects were discussed: (1) Clinical phenotypes, (2) genetics, (3) epigenetics, (4) biomarker discovery, (5) application of precision biology to clinical trials, (6) the right ventricle (RV), and (7) integrating precision medicine to clinical care. The present review summarizes the content of these discussions and the prospects for the future.
Keywords
- biomarker
- epigenetics
- genomics‐metabolomics‐proteomics
- pulmonary hypertension
- right ventricle function and dysfunction
